Susana Perez-Gutthann

RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Search Publications

Filter

Filter by Year

Search Results

Metadata for Data dIscoverability aNd Study rEplicability in obseRVAtional Studies (MINERVA): Development and Pilot of a Metadata List and Catalogue in Europe

Metadata for Data dIscoverability aNd Study rEplicability in obseRVAtional Studies (MINERVA): Lessons Learnt From the MINERVA Project in Europe

Lessons learned from a multi-data source research collaboration: The mirabegron post-authorization safety study program

Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Post-authorization safety study based on multinational cohorts

Post-authorization safety study (PASS) assessing the risk of liver, renal, genitourinary, and diabetic ketoacidosis outcomes among users of empagliflozin versus DPP-4 inhibitors in patients with type 2 diabetes mellitus (T2D)

HARmonized protocol template to enhance reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force

HARmonized protocol template to enhance reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force

Risk assessment of acute myocardial infarction and stroke associated with long-acting muscarinic antagonists, alone or in combination, versus long-acting beta2-agonists

Incidence of acute renal failure in patients using levetiracetam versus other antiseizure medications: A voluntary post-authorization safety study

Characteristics of new users of aclidinium bromide, aclidinium/formoterol, and other COPD medications in the United Kingdom, Denmark, and Germany

Where to begin?: Thirty must-read papers for newcomers to pharmacoepidemiology

Long-term risk of skin cancer and lymphoma in users of topical tacrolimus and pimecrolimus: Final results from the extension of the cohort study protopic joint European longitudinal lymphoma and skin cancer evaluation (JOELLE)

Use of intravenous iron and risk of anaphylaxis: A multinational observational post-authorisation safety study in Europe

Cardiovascular risk in users of mirabegron compared with users of antimuscarinic treatments for overactive bladder: Findings from a non-interventional, multinational, cohort study

A cohort study to evaluate the risk of hospitalisation for congestive heart failure associated with the use of aclidinium and other chronic obstructive pulmonary disease medications in the UK clinical practice research datalink

A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder

Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom

Comparative cardiovascular safety of strontium ranelate and bisphosphonates: A multi-database study in 5 EU countries by the EU-ADR Alliance

Characteristics of new users of aclidinium, aclidinium/formoterol, and other COPD medications in three European countries

A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder